Research suggests that thymoquinone, one of the primary active compounds found in Nigella sativa, may possess anti-inflammatory properties partly through its ability to interact with proteins involved in viral and cellular processes, as indicated by a 2020 computational and laboratory study that tested thymoquinone alongside other natural compounds against SARS-CoV-2 proteins. This study, which combined molecular docking simulations with cytotoxicity testing and plaque reduction assays, found that thymoquinone showed potential binding affinity to the virus's main protease, a target relevant to inflammation-associated viral replication. However, the evidence base summarized here is limited to a single preclinical and computational study, which represents an early stage of research and cannot establish clinical efficacy in humans. Readers should note that computational binding predictions and in vitro findings do not always translate to real-world therapeutic outcomes, and more rigorous human trials would be necessary to draw firm conclusions about Nigella sativa's anti-inflammatory effects.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| In vitro: Natural Compounds (Thymol, Carvacrol, Hesperidine, And Thymoquinone... | Other | 2020 | Supports | 85 |